Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Peptide-directed highly selective targeting of pulmonary arterial hypertension.

Urakami T, Järvinen TA, Toba M, Sawada J, Ambalavanan N, Mann D, McMurtry I, Oka M, Ruoslahti E, Komatsu M.

Am J Pathol. 2011 Jun;178(6):2489-95. doi: 10.1016/j.ajpath.2011.02.032. Epub 2011 May 6.

2.

The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.

Sakao S, Tatsumi K.

Respiration. 2011;81(3):253-61. doi: 10.1159/000322011. Epub 2010 Nov 30. Review.

3.

The monocrotaline model of pulmonary hypertension in perspective.

Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ.

Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9. doi: 10.1152/ajplung.00212.2011. Epub 2011 Sep 30. Review.

PMID:
21964406
4.

Pathology of pulmonary hypertension.

Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB.

Clin Chest Med. 2013 Dec;34(4):639-50. doi: 10.1016/j.ccm.2013.08.009. Epub 2013 Oct 17. Review.

PMID:
24267295
5.

The metabolic basis of pulmonary arterial hypertension.

Sutendra G, Michelakis ED.

Cell Metab. 2014 Apr 1;19(4):558-73. doi: 10.1016/j.cmet.2014.01.004. Epub 2014 Feb 6. Review.

6.

Drug-induced pulmonary arterial hypertension: a review.

Garg L, Akbar G, Agrawal S, Agarwal M, Khaddour L, Handa R, Garg A, Shah M, Patel B, Dalal BD.

Heart Fail Rev. 2017 May;22(3):289-297. doi: 10.1007/s10741-017-9612-9. Review.

PMID:
28417295
7.

Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.

Nakamura K, Matsubara H, Akagi S, Sarashina T, Ejiri K, Kawakita N, Yoshida M, Miyoshi T, Watanabe A, Nishii N, Ito H.

J Clin Med. 2017 Apr 29;6(5). pii: E48. doi: 10.3390/jcm6050048. Review.

Supplemental Content

Support Center